Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06423430 · ClinicalTrials.gov registry record · NA

Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)

A NA study of Treatment-Resistant Depression, sponsored by Abbott Medical Devices.

Recruiting
Registry status
NA
Development phase
100
Enrollment target
20
Study locations

NCT06423430 is a NA study of Treatment-Resistant Depression that is actively recruiting participants, run by Abbott Medical Devices. The registered enrollment target is 100 participants, below the 372-participant average among 54 other Treatment-Resistant Depression trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06423430, a NA study of Treatment-Resistant Depression, is actively recruiting participants, sponsored by Abbott Medical Devices.

RECRUITING
Registry status
NA
Development phase
100 participants
Enrollment target
20
Study locations

Study Summary

The goal of this clinical trial is to evaluate the effectiveness and safety of bilateral stimulation of the subcallosal cingulate white matter (SCCwm) using Deep Brain Stimulation (DBS) as an adjunctive treatment of non-psychotic unipolar Major Depressive Disorder (MDD) in adults.

Conditions Studied

Treatment-Resistant Depression

Interventions

  • DEVICE Sham-stimulation
  • DEVICE Active-stimulation

Study Locations (20)

California

  • USC University Hospital - Los Angeles
  • UCLA Department of Psychiatry - Los Angeles
  • University of California at Davis - Sacramento

Illinois

  • Rush University Medical Center - Chicago
  • University of Chicago - Chicago

Massachusetts

  • Massachusetts General Hospital - Boston
  • Beth Israel Deaconess Medical Center - Boston

Minnesota

  • University of Minnesota Medical Center Fairview - Minneapolis
  • Mayo Clinic - Rochester

Ohio

  • The Cleveland Clinic Foundation - Cleveland
  • The Ohio State University - Columbus

Alabama

  • University of Alabama at Birmingham - Dept. of Psychiatry - Birmingham

Florida

  • USF Health - Tampa

Georgia

  • Emory University Hospital - Atlanta

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2024-09-11
Est. Completion 2029-04
Phase NA

Sponsor

Abbott Medical Devices

261 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06423430

The ClinicalTrials.gov registry entry for NCT06423430 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 372-participant average among 54 other Treatment-Resistant Depression trials with a reported enrollment target (73% lower). The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Treatment-Resistant Depression appearing as the primary indexed condition, and to 2 interventions - of which Sham-stimulation is the first listed.

NCT06423430 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Illinois, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06423430 about?

NCT06423430 is a clinical study titled "Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)". The goal of this clinical trial is to evaluate the effectiveness and safety of bilateral stimulation of the subcallosal cingulate white matter (SCCwm) using Deep Brain Stimulation (DBS) as an adjunctive treatment of non-psychotic unipolar Major Depressive Disorder (MDD) in adults.

What is the current status of trial NCT06423430?

This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2024-09-11. Estimated completion is 2029-04.

What conditions does trial NCT06423430 study?

This clinical trial studies the following conditions: Treatment-Resistant Depression.

What interventions are being tested in trial NCT06423430?

The interventions under investigation include: Sham-stimulation (DEVICE), Active-stimulation (DEVICE).

Who is sponsoring clinical trial NCT06423430?

This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06423430 being conducted?

This trial has 20 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Treatment-Resistant Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Treatment-Resistant Depression

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.